Attenuated TechnologiesFounder & Principal — Michael Churchill

Selected Experience

Representative Companies

These companies represent founder roles, full-time executive employment, and selected operating engagements. They are evidence of Michael's broader career, not a client list for Attenuated Technologies.

Brahma Therapeutics

Brahma Therapeutics was formed around a de novo peptide-engineering platform and the opportunity to translate foundational academic technologies into a biotechnology company.

Michael's role
Founder & Chief Scientist. Michael negotiated foundational licenses, defined the platform and development strategy, and built the scientific operation from concept through proof of concept.
Outcome
Brahma was positioned for and reached a strategic acquisition outcome in May 2023.
View Engagement

MultiOmics

MultiOmics is an AI-native precision-diagnostics company focused on early breast-cancer detection.

Michael's role
Interim CSO/CBO through Attenuated Technologies. Michael leads scientific development, operating coordination, corporate strategy, business-development support, and AI strategy.
Outcome
Selected for the 2025 C10/LabCentral AI-BioHub cohort. Michael created the application and pitch materials used during the program.
View Engagement

CREATE Medicines / Myeloid Therapeutics

CREATE Medicines, formerly Myeloid Therapeutics, is a clinical-stage biotechnology company advancing in vivo CAR programs through first-in-human development.

Michael's role
Senior Director, Translational Science. Michael led biomarker strategy and translational execution for MT302 and directed cross-functional startup of multinational Phase I program MT303.
Outcome
Michael's translational work supported full enrollment of MT302 in under 12 months. MT303 expanded the clinical pipeline and international operating footprint.
View Engagement

SEngine Precision Medicine

SEngine developed a functional precision-oncology platform intended to move from assay development into a CLIA-certified clinical diagnostic service.

Michael's role
Lead Scientist, then Principal Scientist. Michael built the CLIA-certified P.A.R.I.S. test and later supported its physician-facing clinical implementation and broader company development.
Outcome
Michael developed personalized drug panels for more than 100 cancer patients and supported an approximately $9 million financing through financial analysis, valuation work, diligence materials, and company presentations. The CEO led the financing.
View Engagement

Representative engagement

Brahma Therapeutics

Brahma Therapeutics was formed around a de novo peptide-engineering platform and the opportunity to translate foundational academic technologies into a biotechnology company.

Challenge
The company needed a defensible scientific and commercial foundation, access to core intellectual property, and an operating platform capable of moving from concept toward translational readiness.
Strategic Premise
Brahma brought foundational technologies, scientific strategy, and operating capability together to advance a new peptide-engineering platform.
Michael's Role
Founder & Chief Scientist. Michael negotiated foundational licenses, defined the platform and development strategy, and built the scientific operation from concept through proof of concept.
Technology and Execution Context
De novo peptide engineering, synthetic biology, platform strategy, translational science, intellectual-property licensing, and CMC development.
Outcome
Brahma was positioned for and reached a strategic acquisition outcome in May 2023.

Timeline

  1. Company building

    From intellectual property to strategic readiness

    Michael connected foundational licenses, platform formation, operating capability, and translational evidence into a coherent company-building program.

Representative engagement

MultiOmics

MultiOmics is an AI-native precision-diagnostics company focused on early breast-cancer detection.

Challenge
An early-stage diagnostics company needed integrated scientific, operating, and corporate strategy to advance its concept and establish a credible development path.
Strategic Premise
MultiOmics is pursuing a precision-diagnostics strategy for earlier breast-cancer detection, bringing scientific, business, and AI strategy together around a consequential clinical problem.
Michael's Role
Interim CSO/CBO through Attenuated Technologies. Michael leads scientific development, operating coordination, corporate strategy, business-development support, and AI strategy.
Technology and Execution Context
Precision diagnostics, early cancer detection, scientific strategy, and AI-enabled research and organizational workflows.
Outcome
Selected for the 2025 C10/LabCentral AI-BioHub cohort. Michael created the application and pitch materials used during the program.

Timeline

  1. Current engagement

    Integrated scientific and executive leadership

    Michael serves as Interim CSO/CBO through Attenuated Technologies.

Representative engagement

CREATE Medicines / Myeloid Therapeutics

CREATE Medicines, formerly Myeloid Therapeutics, is a clinical-stage biotechnology company advancing in vivo CAR programs through first-in-human development.

Challenge
The organization needed translational and biomarker strategies that could connect complex platform science with clinical execution across research, clinical development, regulatory, clinical operations, manufacturing, bioanalytics, and external partners.
Strategic Premise
Translational strategy and biomarkers would connect platform science, patient evidence, and cross-functional execution across first-in-human clinical development.
Michael's Role
Senior Director, Translational Science. Michael led biomarker strategy and translational execution for MT302 and directed cross-functional startup of multinational Phase I program MT303.
Technology and Execution Context
In vivo CAR, translational medicine, clinical biomarkers, bioanalytics, precision medicine, and first-in-human clinical development.
Outcome
Michael's translational work supported full enrollment of MT302 in under 12 months. MT303 expanded the clinical pipeline and international operating footprint.

Timeline

  1. Clinical execution

    MT302 and MT303 Phase I programs

    Michael connected translational strategy with coordinated clinical delivery across two first-in-human programs.

Representative engagement

SEngine Precision Medicine

SEngine developed a functional precision-oncology platform intended to move from assay development into a CLIA-certified clinical diagnostic service.

Challenge
A functional drug-screening platform needed to become a regulated clinical product supported by automation, quality systems, physician-facing interpretation, and adoption in real-world care.
Strategic Premise
Functional testing could complement molecular diagnostics by helping physicians interpret drug response in the context of disease, genomic findings, treatment history, pathology, and the clinical question.
Michael's Role
Lead Scientist, then Principal Scientist. Michael built the CLIA-certified P.A.R.I.S. test and later supported its physician-facing clinical implementation and broader company development.
Technology and Execution Context
Functional precision oncology, clinical diagnostics, automation, quality systems, physician decision support, and commercialization.
Outcome
Michael developed personalized drug panels for more than 100 cancer patients and supported an approximately $9 million financing through financial analysis, valuation work, diligence materials, and company presentations. The CEO led the financing.

Timeline

  1. Commercialization

    From research platform to clinical use

    Michael helped translate functional drug screening into a CLIA-certified test supported by clinical-grade quality systems and physician-facing workflows.